Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.
In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...
The T cell receptor (TCR)-CD3 complex is crucial to adaptive immunity, driving antigen recognition and intracellular signaling cascades. CD3 subunits harbor key cytoplasmic motifs that recruit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback